The subscription price for warrants of series TO 5 B has been set at SEK 0.46 per share
Lund, Sweden – Clinical Laserthermia Systems AB ("CLS" or the "Company") hereby announces the subscription price for the exercise of warrants of series TO 5 B, which were issued in connection with the Company's rights issue of units that was announced on 10 August 2022. The subscription price for warrants of series TO 5 B has been set at SEK 0.46 per share and the exercise period begins tomorrow, 14 February 2023.
In connection with the Company's rights issue of units that was announced on 10 August 2022, CLS issued 27,722,620 warrants of series TO 5 B.
Each warrant of series TO 5 B entitles the holder to subscribe for one (1) new B-share in CLS during the exercise period that runs from 14 February 2023 until 28 February 2023. The subscription price for warrants of series TO 5 B has been set at SEK 0.46 per share, which corresponds to seventy (70) percent of the average volume-weighted price of the B-share according to Nasdaq First North Growth Market's official price statistics during the period from and including 30 January 2023 to and including 10 February 2023. At full utilization of warrants of series TO 5 B, the Company will be provided proceeds of approximately SEK 12.8 million before deduction of transaction related costs.
Upon full exercise of warrants of series TO 5 B, the number of shares in CLS will increase by 27,722,620 B-shares to a total of 162,844,439 shares (of which 162,244,439 B-shares) and the share capital will increase by approximately SEK 2,564,342.36 to SEK 15,063,110.69. The dilution at full utilization amounts to approximately 17 percent of the capital and 16.5 percent of the votes.
Complete terms and conditions for warrants of series TO 5 B are available on the Company's website (www.clinicallaser.se). An information brochure containing summary information about the Company and the warrant exercise will be available on the websites of CLS, Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).
Important dates
• 14 February 2023: The exercise period begins
• 24 February 2023: Last day of trading in warrants
• 28 February 2023: The exercise period ends
• 1-3 March 2023: Planned communication of the outcome of the warrant exercise
• 24 March 2023: Planned conversion of interim shares to B-shares
Advisors
In connection with the exercise of warrants of series TO 5 B, Sedermera Corporate Finance AB is acting as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB is assisting the Company with advise regarding communication.
For more information about the warrants of series TO 5 B, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
For more information about CLS, please contact:
Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
www.clinicallaser.se
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide™ Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se
For more information about CLS, please visit the Company's website: www.clinicallaser.se